News Release – Dec 6, 2022
AMO Pharma Announces Completion of Enrollment in REACH-CDM Study in Congenital Myotonic Dystrophy
News Release – May 10, 2022
AMO Pharma Announces Additional Private Equity Investment Following Progress in Phase 3 Study in Congenital Myotonic Dystrophy
News Release – Dec 22, 2021
AMO Pharma Announces Expansion of Pivotal REACH-CDM Study in Congenital Myotonic Dystrophy
News Release – Oct 14, 2021
Julia Jones Joins Amo Pharma as Chief Financial Officer and Board Member
News Release – Sept 30, 2021
AMO Pharma Announces First Patient Enrolled in REACH-CDM X 12-month Open-label Study
News Release – Aug 19, 2021
Accomplished Industry Executive Alan L. Rubino Named Chairman of AMO Pharma Board of Directors
News Release – Aug 17, 2021
AMO Pharma Awarded Innovation Passport for AMO-02 (Tideglusib) for Treatment of Congenital Myotonic Dystrophy Type 1
News Release – May 17, 2021
AMO Pharma Announces Activation of Additional Clinical Trial Sites for Pivotal REACH-CDM Study in Congenital Myotonic Dystrophy
News Release – March 3, 2021
AMO Pharma to Participate in Myotonic Dystrophy Foundation "Meet the DM Drug Developers" Program on March 5, 2021
News Release – December 22, 2020
AMO Pharma Announces Initiation of Pivotal REACH-CDM Clinical Trial for AMO-02 in Treatment of Congenital Myotonic Dystrophy
News Release – November 9, 2020
FDA Grants Rare Pediatric Disease Designation to AMO Pharma for AMO-02 for Treatment of Congenital Myotonic Dystrophy
News Release – February 28, 2020
AMO Pharma to Present at Cowen and Company 40th Annual Health Care Conference
News Release – January 9, 2020
AMO Pharma Announces Initiation of Planned Pivotal Clinical Trial for Myotonic Dystrophy Following $35m Fund Raise
News Release – September 16, 2019
AMO Pharma Participates in Workshop on Central Nervous System Involvement in Progression and Treatment of Myotonic Dystrophy During Myotonic Dystrophy Foundation Annual Conference
News Release – June 13, 2019
Updates on Development of AMO Pharma's AMO-02 Presented at International Myotonic Dystrophy Consortium Meeting
News Release - May 6, 2019
AMO Pharma Presents Statistical Analysis of Results of Phase 2 Study of AMO-02 in Adolescents with Autism Spectrum Disorder
News Release - April 16, 2019
AMO Pharma Announces Launch of First Clinician-Completed Rating Scale for Congenital Myotonic Dystrophy Type 1
News Release - October 29, 2018
AMO Pharma Reports Positive Data from Investigator-Led TIDE Study of AMO-02 in Autism Spectrum Disorder
News Release - October 23, 2018
AMO Therapeutics Announces Presentation of Concordant Analysis of Results of Phase 2 Study of AMO-02 in treatment of myotonic dystrophy
News Release - June 13, 2018
AMO Pharma Receives FDA Orphan Drug Designation for AMO-04 in Treatment of Rett Syndrome
News Release - May 7, 2018
AMO Pharma Announces Initiation of Clinical Trial conducted by Mount Sinai to Study AMO-01 in Treatment of Phelan-McDermid Syndrome
News Release - March 15, 2018
AMO Pharma Announces Results of Phase 2 Proof-of-Concept Study of AMO-02 in Congenital and Childhood Onset Myotonic Dystrophy Type 1
News Release - October 18, 2017
AMO Pharma Presents Positive Interim Analysis of Data from Congenital Myotonic Dystrophy Study at American Neurological Association Annual Meeting
News Release - September 25, 2017
AMO Pharma Reports Update on Positive Interim Analysis for the First Cohort of Phase IIa Congenital Myotonic Dystrophy Study
News Release - July 20, 2017
AMO Pharma Enters into Development and License Agreement with Numedicus Limited for Rett Syndrome Program
News Release - May 30, 2017
AMO Pharma Announces FDA Fast Track Designation For AMO-02 For Treatment Of Congenital Myotonic Dystrophy
News Release - March 14, 2017
AMO Pharma Enters into Collaboration Agreement with Ranedis Pharmaceuticals for Development of RND-001
News Release - February 28, 2017
AMO Pharma Joins with Leaders in Patient and Caregiver Advocacy to Commemorate Rare Disease Day
News Release - August 10, 2016
AMO Pharma Initiates Phase 2 Clinical Trial in UK for AMO-02 for Treatment of Congenital and Juvenile Onset Myotonic Dystrophy
News Release - June 7, 2016
AMO Pharma Presents Pre-clinical Data Showing AMO-01 Successfully Inhibits Activated Pathway Associated with Fragile X Syndrome
News Release - Apr 18, 2016
Joseph Horrigan Joins AMO Pharma as Chief Medical Officer
News Release - Sept 30, 2015
AMO Pharma Ltd. Closes $25M Private Equity Financing with Woodford Patient Capital Trust plc